 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- UB-313 / Vaxxinity
UB-313, an Investigational CGRP Vaccine for the Prevention of Migraine (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2058;
Background Objective Design/Methods Results Conclusions
- || UB-313 / Vaxxinity
Enrollment closed: A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants (clinicaltrials.gov) - Mar 8, 2023
P1, N=40, Active, not recruiting, Sponsor: Vaxxinity, Inc.
Background Objective Design/Methods Results Conclusions Recruiting --> Active, not recruiting
- || UB-313 / Vaxxinity
New P1 trial: A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants (clinicaltrials.gov) - Jul 28, 2022
P1, N=40, Recruiting, Sponsor: Vaxxinity, Inc.